A Non-Randomized, Multicenter, Retrospective Lesion-Based Study Comparing Midterm Angiographic Outcomes of Second Generation Drug-Eluting Stents (Everolimus-Eluting Stents and Biolimus-Eluting Stents) Versus First Generation Drug-Eluting Stents (Sirolimus-Eluting Stents)

Trial Profile

A Non-Randomized, Multicenter, Retrospective Lesion-Based Study Comparing Midterm Angiographic Outcomes of Second Generation Drug-Eluting Stents (Everolimus-Eluting Stents and Biolimus-Eluting Stents) Versus First Generation Drug-Eluting Stents (Sirolimus-Eluting Stents)

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Everolimus (Primary) ; Umirolimus (Primary) ; Sirolimus
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top